Tags

Type your tag names separated by a space and hit enter

Fibroblast growth factor 23 and its receptors.
Ther Apher Dial. 2005 Aug; 9(4):308-12.TA

Abstract

Fibroblast growth factor 23 (FGF23) is a circulating factor that plays critical roles in phosphate and vitamin D metabolism, as evidenced by the fact that FGF23 missense mutations cause autosomal dominant hypophosphatemic rickets (ADHR). Autosomal dominant hypophosphatemic rickets is characterized by hypophosphatemia with inappropriately normal 1,25-dihydroxyvitamin D concentrations, as well as bone pain, fracture and rickets. This phenotype parallels that of patients with tumor induced osteomalacia (TIO), X-linked hypophosphatemic rickets (XLH), and fibrous dysplasia (FD), in whom elevated serum FGF23 levels are often observed. The fibroblast growth factor receptors (FGFR1-4) play key roles in skeletal development, as well as in normal metabolic processes. Several FGFR isoforms that potentially mediate the activity of FGF23 have been implicated. In the short term, these findings will lead to further understanding of FGF23 function, and potentially in the long term, to targeted therapies in disorders of hypo- and hyperphosphatemia that involve FGF23.

Authors+Show Affiliations

Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16076372

Citation

Yu, Xijie, and Kenneth E. White. "Fibroblast Growth Factor 23 and Its Receptors." Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, vol. 9, no. 4, 2005, pp. 308-12.
Yu X, White KE. Fibroblast growth factor 23 and its receptors. Ther Apher Dial. 2005;9(4):308-12.
Yu, X., & White, K. E. (2005). Fibroblast growth factor 23 and its receptors. Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 9(4), 308-12.
Yu X, White KE. Fibroblast Growth Factor 23 and Its Receptors. Ther Apher Dial. 2005;9(4):308-12. PubMed PMID: 16076372.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fibroblast growth factor 23 and its receptors. AU - Yu,Xijie, AU - White,Kenneth E, PY - 2005/8/4/pubmed PY - 2005/12/15/medline PY - 2005/8/4/entrez SP - 308 EP - 12 JF - Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy JO - Ther Apher Dial VL - 9 IS - 4 N2 - Fibroblast growth factor 23 (FGF23) is a circulating factor that plays critical roles in phosphate and vitamin D metabolism, as evidenced by the fact that FGF23 missense mutations cause autosomal dominant hypophosphatemic rickets (ADHR). Autosomal dominant hypophosphatemic rickets is characterized by hypophosphatemia with inappropriately normal 1,25-dihydroxyvitamin D concentrations, as well as bone pain, fracture and rickets. This phenotype parallels that of patients with tumor induced osteomalacia (TIO), X-linked hypophosphatemic rickets (XLH), and fibrous dysplasia (FD), in whom elevated serum FGF23 levels are often observed. The fibroblast growth factor receptors (FGFR1-4) play key roles in skeletal development, as well as in normal metabolic processes. Several FGFR isoforms that potentially mediate the activity of FGF23 have been implicated. In the short term, these findings will lead to further understanding of FGF23 function, and potentially in the long term, to targeted therapies in disorders of hypo- and hyperphosphatemia that involve FGF23. SN - 1744-9979 UR - https://www.unboundmedicine.com/medline/citation/16076372/Fibroblast_growth_factor_23_and_its_receptors_ L2 - https://doi.org/10.1111/j.1744-9987.2005.00287.x DB - PRIME DP - Unbound Medicine ER -